<DOC>
	<DOCNO>NCT01691781</DOCNO>
	<brief_summary>This study evaluate whether commonly use blood pressure medication call `` ACE inhibitor '' low parathyroid hormone .</brief_summary>
	<brief_title>The Renin-Angiotensin-Aldosterone System Parathyroid Hormone Control : The RAAS-PARC Study</brief_title>
	<detailed_description>The RAAS-PARC study evaluate whether angiotensin-converting enzyme inhibitor ( ACEi ) low parathyroid hormone ( PTH ) normal control individual diagnosis primary hyperparathyroidism . Emerging data implicate renin-angiotensin-aldosterone system ( RAAS ) activity increase PTH . The principal investigator , investigator , previously show inhibit RAAS may lower PTH . The current study focus : 1 . Normal Physiology : Does ACEi ( lower angiotensin II aldosterone ) reduce PTH normal individual ? 2 . Pathophysiology : Does ACEi reduce PTH individual primary hyperparathyroidism ? The result study may important implication cardiovascular skeletal health , RAAS PTH implicate mediator condition .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Captopril</mesh_term>
	<criteria>Healthy subject medical problem ( n=15 ) individual primary hyperparathyroidism ( n=30 ) normal blood pressure stage 1 hypertension either untreated , adequately treat single antihypertensive medication . Age &gt; 18 year &lt; 80 year Estimated GFR &gt; 60ml/min Chronic Kidney Disease eGFR &lt; 60 Stage 2 Stage 3 hypertension use 1 antihypertensive drug Type 2 Diabetes Mellitus control diet Metformin alone Hemoglobin A1c &gt; 7.5 % History liver failure History heart failure The use typical atypical antipsychotic medication lithium . Chronic inflammatory condition ( inflammatory bowel disease arthritis ) treat prescribed dos NSAIDs glucocorticoids The use prescribed dos potassium supplement . Illness require overnight hospitalization past 6 month Active tobacco recreational drug use Pregnancy current breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Renin-angiotensin-aldosterone system</keyword>
	<keyword>ACE inhibitor</keyword>
</DOC>